| Literature DB >> 29555649 |
Yu-Tang Chin1,2, Po-Li Wei3,4,5, Yih Ho6, André Wendindondé Nana1,7, Chun A Changou2,8,9, Yi-Ru Chen1,2, Yu-Chen Sh Yang10, Meng-Ti Hsieh2, Aleck Hercbergs11, Paul J Davis12,13, Ya-Jung Shih2, Hung-Yun Lin1,2,14.
Abstract
Thyroid hormone, l-thyroxine (T4), has been shown to promote ovarian cancer cell proliferation via a receptor on plasma membrane integrin αvβ3 and to induce the activation of ERK1/2 and expression of programmed death-ligand 1 (PD-L1) in cancer cells. In contrast, resveratrol binds to integrin αvβ3 at a discrete site and induces p53-dependent antiproliferation in malignant neoplastic cells. The mechanism of resveratrol action requires nuclear accumulation of inducible cyclooxygenase (COX)-2 and its complexation with phosphorylated ERK1/2. In this study, we examined the mechanism by which T4 impairs resveratrol-induced antiproliferation in human ovarian cancer cells and found that T4 inhibited resveratrol-induced nuclear accumulation of COX-2. Furthermore, T4 increased expression and cytoplasmic accumulation of PD-L1, which in turn acted to retain inducible COX-2 in the cytoplasm. Knockdown of PD-L1 by small hairpin RNA (shRNA) relieved the inhibitory effect of T4 on resveratrol-induced nuclear accumulation of COX-2- and COX-2/p53-dependent gene expression. Thus, T4 inhibits COX-2-dependent apoptosis in ovarian cancer cells by retaining inducible COX-2 with PD-L1 in the cytoplasm. These findings provide new insights into the antagonizing effect of T4 on resveratrol's anticancer properties.Entities:
Keywords: zzm321990l-thyroxine; COX-2; PD-L1; ovarian cancer; resveratrol
Mesh:
Substances:
Year: 2018 PMID: 29555649 DOI: 10.1530/ERC-17-0376
Source DB: PubMed Journal: Endocr Relat Cancer ISSN: 1351-0088 Impact factor: 5.678